Dbv Technologies ADR (DBVT)

$20.00 -0.36 (-1.77%)
Market Cap 1.13B
Revenue (ttm) 5.64M
Net Income (ttm) -146.95M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -2,605.50%
Debt to Equity Ratio 0.00
Volume 174,500
Avg Vol 247,970
Day's Range N/A - N/A
Shares Out 55.67M
Stochastic %K 44%
Beta -0.96
Analysts Strong Sell
Price Target $41.00

Company Profile

DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products in France. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow's milk protein allergy and eosinophilic esophagitis. The company's earlie...

Industry: Biotechnology
Sector: Healthcare
Phone: 33 1 55 42 78 78
Address:
Bâtiment IRO, 107 Av. de la REpublique, Châtillon, France
Mortimer2020
Mortimer2020 Apr. 8 at 2:10 PM
$DBVT where are we at with getting this thing to market
0 · Reply
focafoca99
focafoca99 Apr. 3 at 9:02 PM
$DBVT release the monthly share-count and voting-rights disclosure as of March 31.
0 · Reply
WallStreetBuyDip
WallStreetBuyDip Apr. 3 at 6:13 PM
$DBVT Massive volume spike of 446,600 shares traded, well over 2x the average volume. Price staying around $21.06, with highs at $24.54 and lows at $6.50. Recent price action has been quite active with significant volume increases. Waiting for a lower H% before considering entry.
0 · Reply
RunnerSignals
RunnerSignals Apr. 3 at 1:27 PM
$VSAT $AAOI $AXTI $KURA $DBVT RSI flip = early money signal not extended yet, setups still developing https://stocksrunner.com/news/2026-04-03-momentum-rsi-breakout
0 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Mar. 26 at 12:23 PM
$DBVT RSI: 40.70, MACD: -0.4956 Vol: 1.38, MA20: 21.02, MA50: 21.42 🟢 BUY - Uptrend + healthy RSI 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
OpenOutcrier
OpenOutcrier Mar. 25 at 12:14 PM
$DBVT (+5.6% pre) DBV Technologies to Join CAC Mid 60 and SBF 120 Indices Following Euronext Paris Annual Review https://ooc.bz/l/97133
0 · Reply
thejaygatsby
thejaygatsby Mar. 24 at 2:14 PM
$DBVT earnings are today right?
0 · Reply
Zamboni18
Zamboni18 Mar. 12 at 1:40 PM
$DBVT
0 · Reply
medguy
medguy Mar. 12 at 4:16 AM
Looking for bounce $DBVT
0 · Reply
focafoca99
focafoca99 Mar. 3 at 10:47 PM
$DBVT dropped a voting-rights/share-count update.
0 · Reply
Latest News on DBVT
DBV Technologies to Participate in the H.C. Wainwright 4th Annual BioConnect Investor Conference at Nasdaq

Tue, 12 May 2026 16:30:00 -0400 - 16 hours ago

DBV Technologies to Participate in the H.C. Wainwright 4th Annual BioConnect Investor Conference at Nasdaq

DBVT Reiterated by Guggenheim -- Price Target Maintained at $51.00

2026-05-04T15:00:44.000Z - 8 days ago

DBVT Reiterated by Guggenheim -- Price Target Maintained at $51.00

DBVT Maintained by Citizens -- Price Target Raised to $55.00

2026-05-01T18:33:55.000Z - 11 days ago

DBVT Maintained by Citizens -- Price Target Raised to $55.00

DBV Technologies price target raised to $55 from $47 at Citizens

2026-05-01T09:56:39.000Z - 12 days ago

DBV Technologies price target raised to $55 from $47 at Citizens

DBVT

DBVT SWOT Analysis: Financial Challenges and Growth Potential Revealed in 10-Q Filing

2026-05-01T05:15:38.000Z - 12 days ago

DBVT SWOT Analysis: Financial Challenges and Growth Potential Revealed in 10-Q Filing

Is DBV Technologies (DBVT) Fairly Valued After Q1 2026 Results? EPS $(0. ...

2026-04-30T22:54:24.000Z - 12 days ago

Is DBV Technologies (DBVT) Fairly Valued After Q1 2026 Results? EPS $(0. ...

DBVT Advances Peanut Allergy Treatments with Upcoming Clinical Studies

2026-04-30T22:45:03.000Z - 12 days ago

DBVT Advances Peanut Allergy Treatments with Upcoming Clinical Studies

DBV Technologies reports Q1 EPS (11c), consensus (12c)

2026-04-30T21:15:57.000Z - 12 days ago

DBV Technologies reports Q1 EPS (11c), consensus (12c)

DBVT

DBV Technologies Reports First Quarter 2026 Financial Results

Thu, 30 Apr 2026 16:30:00 -0400 - 12 days ago

DBV Technologies Reports First Quarter 2026 Financial Results

DBV Technologies price target lowered to EUR 1.01 from EUR 1.37 at Goldman Sachs

2026-04-09T16:15:48.000Z - 4 weeks ago

DBV Technologies price target lowered to EUR 1.01 from EUR 1.37 at Goldman Sachs

DBVT

DBV Technologies S.A.: Information Regarding the Total Number of Voting Rights and Total Number of Shares of the Company as of March 31, 2026

2026-04-02T20:34:00.000Z - 5 weeks ago

DBV Technologies S.A.: Information Regarding the Total Number of Voting Rights and Total Number of Shares of the Company as of March 31, 2026

Information Regarding the Total Number of Voting Rights and Total Number of Shares of the Company as of March 31, 2026

Apr 2, 2026, 4:30 PM EDT - 5 weeks ago

Information Regarding the Total Number of Voting Rights and Total Number of Shares of the Company as of March 31, 2026

DBVT

DBV Technologies price target raised to $47 from $45 at Citizens

2026-03-27T09:40:13.000Z - 6 weeks ago

DBV Technologies price target raised to $47 from $45 at Citizens

DBVT

DBV Technologies S.A.: DBV Technologies Announces Filing of 2025 Annual Report on Form 10-K and Universal Registration Document

2026-03-26T21:34:00.000Z - 6 weeks ago

DBV Technologies S.A.: DBV Technologies Announces Filing of 2025 Annual Report on Form 10-K and Universal Registration Document

DBV Technologies S.A.: DBV Technologies Reports Full Year 2025 Financial Results and Business Update

2026-03-26T21:22:00.000Z - 6 weeks ago

DBV Technologies S.A.: DBV Technologies Reports Full Year 2025 Financial Results and Business Update

DBV Technologies Announces Filing of 2025 Annual Report on Form 10-K and Universal Registration Document

Mar 26, 2026, 5:19 PM EDT - 6 weeks ago

DBV Technologies Announces Filing of 2025 Annual Report on Form 10-K and Universal Registration Document

DBVT

DBV Technologies Reports Full Year 2025 Financial Results and Business Update

Mar 26, 2026, 5:06 PM EDT - 6 weeks ago

DBV Technologies Reports Full Year 2025 Financial Results and Business Update

DBVT

DBV Technologies S.A.: DBV Technologies to Join CAC Mid 60 and SBF 120 Indices Following Euronext Paris Annual Review

2026-03-24T20:34:00.000Z - 7 weeks ago

DBV Technologies S.A.: DBV Technologies to Join CAC Mid 60 and SBF 120 Indices Following Euronext Paris Annual Review

DBV Technologies to Join CAC Mid 60 and SBF 120 Indices Following Euronext Paris Annual Review

Mar 24, 2026, 4:30 PM EDT - 7 weeks ago

DBV Technologies to Join CAC Mid 60 and SBF 120 Indices Following Euronext Paris Annual Review

DBVT

DBV Technologies Transcript: The Citizens Life Sciences Conference 2026

Mar 10, 2026, 1:40 PM EDT - 2 months ago

DBV Technologies Transcript: The Citizens Life Sciences Conference 2026

DBV Technologies to Participate in Upcoming March Investor Conferences

Mar 4, 2026, 4:30 PM EST - 2 months ago

DBV Technologies to Participate in Upcoming March Investor Conferences

DBVT

DBV Technologies announces Phase 3 Vitesse trial met primary endpoint

2026-03-01T16:20:07.000Z - 2 months ago

DBV Technologies announces Phase 3 Vitesse trial met primary endpoint

DBVT

DBV Technologies Highlights Additional Data from Successful Phase 3 VITESSE Study at the AAAAI 2026 Annual Meeting

Feb 28, 2026, 2:25 PM EST - 2 months ago

DBV Technologies Highlights Additional Data from Successful Phase 3 VITESSE Study at the AAAAI 2026 Annual Meeting

DBVT

DBV Technologies Transcript: Guggenheim Securities Emerging Outlook: Biotech Summit 2026

Feb 12, 2026, 2:30 PM EST - 3 months ago

DBV Technologies Transcript: Guggenheim Securities Emerging Outlook: Biotech Summit 2026

DBV Technologies to Present Additional Data from the VITESSE Phase 3 Study of the VIASKIN® Peanut Patch in Children Ages 4-7 Years and Discuss Future of EPIT in the Treatment Landscape at AAAAI 2026 Annual Meeting

Feb 10, 2026, 4:30 PM EST - 3 months ago

DBV Technologies to Present Additional Data from the VITESSE Phase 3 Study of the VIASKIN® Peanut Patch in Children Ages 4-7 Years and Discuss Future of EPIT in the Treatment Landscape at AAAAI 2026 Annual Meeting

DBVT

Information Regarding the Total Number of Voting Rights and Total Number of Shares of the Company as of January 31, 2026

Feb 5, 2026, 4:30 PM EST - 3 months ago

Information Regarding the Total Number of Voting Rights and Total Number of Shares of the Company as of January 31, 2026

DBVT

DBV Technologies Announces €166.7 Million in Gross Proceeds Following the Full Exercise of the ABSA Warrants and BS Warrants Issued on its March 2025 Financing

Jan 16, 2026, 6:11 PM EST - 4 months ago

DBV Technologies Announces €166.7 Million in Gross Proceeds Following the Full Exercise of the ABSA Warrants and BS Warrants Issued on its March 2025 Financing

DBVT

Information Regarding the Total number of Voting Rights and Total Number of Shares of the Company as of December 31, 2025

Jan 12, 2026, 4:00 PM EST - 4 months ago

Information Regarding the Total number of Voting Rights and Total Number of Shares of the Company as of December 31, 2025

DBVT

Information Regarding the Total Number of Voting Rights and Total Number of Shares of the Company as of December 31, 2025

Jan 5, 2026, 4:00 PM EST - 4 months ago

Information Regarding the Total Number of Voting Rights and Total Number of Shares of the Company as of December 31, 2025

DBVT

DBV Technologies price target raised to $40 from $35 at H.C. Wainwright

2025-12-17T13:55:17.000Z - 5 months ago

DBV Technologies price target raised to $40 from $35 at H.C. Wainwright

DBVT

Peanut Allergy Patch For Kids? DBV Technologies Advances Toward FDA Filing

Dec 17, 2025, 8:49 AM EST - 5 months ago

Peanut Allergy Patch For Kids? DBV Technologies Advances Toward FDA Filing

DBVT

DBV Technologies Stock (DBVT) Soars as Clinical Trial Results Trigger Analyst Price Target Increases

2025-12-17T13:29:17.000Z - 5 months ago

DBV Technologies Stock (DBVT) Soars as Clinical Trial Results Trigger Analyst Price Target Increases

DBV Technologies price target raised to $48 from $42 at Cantor Fitzgerald

2025-12-17T13:16:27.000Z - 5 months ago

DBV Technologies price target raised to $48 from $42 at Cantor Fitzgerald

DBVT

DBV Technologies price target raised to $51 from $35 at Guggenheim

2025-12-17T11:50:22.000Z - 5 months ago

DBV Technologies price target raised to $51 from $35 at Guggenheim

DBVT

DBV Technologies price target raised to $45 from $21 at Citizens

2025-12-17T10:50:54.000Z - 5 months ago

DBV Technologies price target raised to $45 from $21 at Citizens

DBVT

DBV Technologies Transcript: Study Update

Dec 16, 2025, 5:00 PM EST - 5 months ago

DBV Technologies Transcript: Study Update

DBV Technologies trading resumes, shares up 65% to $29.60

2025-12-16T21:56:34.000Z - 5 months ago

DBV Technologies trading resumes, shares up 65% to $29.60

DBVT

DBV Technologies jumps 79% after peanut allergy study hits endpoint

2025-12-16T21:55:46.000Z - 5 months ago

DBV Technologies jumps 79% after peanut allergy study hits endpoint

DBVT

DBV Technologies trading resumes

2025-12-16T21:50:14.000Z - 5 months ago

DBV Technologies trading resumes

DBVT

DBV Technologies reports VITESSE trial meets primary endpoint

2025-12-16T21:15:14.000Z - 5 months ago

DBV Technologies reports VITESSE trial meets primary endpoint

DBVT

DBV Technologies trading halted, news pending

2025-12-16T21:05:26.000Z - 5 months ago

DBV Technologies trading halted, news pending

DBVT

DBV Technologies initiated with an Overweight at Cantor Fitzgerald

2025-12-15T12:55:47.000Z - 5 months ago

DBV Technologies initiated with an Overweight at Cantor Fitzgerald

DBVT

DBV Technologies price target raised to $35 from $20 at H.C. Wainwright

2025-12-15T11:17:10.000Z - 5 months ago

DBV Technologies price target raised to $35 from $20 at H.C. Wainwright

DBVT

DBV Technologies initiated with an Overweight at Cantor Fitzgerald

2025-12-15T00:00:34.000Z - 5 months ago

DBV Technologies initiated with an Overweight at Cantor Fitzgerald

DBVT

Guggenheim starts DBV Technologies at Buy on peanut allergy market potential

2025-12-03T12:20:30.000Z - 5 months ago

Guggenheim starts DBV Technologies at Buy on peanut allergy market potential

DBVT

DBV Technologies initiated with a Buy at Guggenheim

2025-12-03T11:15:39.000Z - 5 months ago

DBV Technologies initiated with a Buy at Guggenheim

DBVT

DBV Technologies Announces Last Patient Visit Completed in VITESSE Phase 3 Clinical Trial of VIASKIN® Peanut Patch in Peanut Allergic Children Aged 4-7 Years

Nov 11, 2025, 11:50 PM EST - 6 months ago

DBV Technologies Announces Last Patient Visit Completed in VITESSE Phase 3 Clinical Trial of VIASKIN® Peanut Patch in Peanut Allergic Children Aged 4-7 Years

DBVT

DBV Technologies Transcript: Guggenheim Securities 2nd Annual Healthcare Innovation Conference

Nov 11, 2025, 2:00 PM EST - 6 months ago

DBV Technologies Transcript: Guggenheim Securities 2nd Annual Healthcare Innovation Conference

DBV Technologies to Participate in the Guggenheim 2nd Annual Healthcare Innovation Conference

Nov 4, 2025, 4:30 PM EST - 6 months ago

DBV Technologies to Participate in the Guggenheim 2nd Annual Healthcare Innovation Conference

DBVT

DBV Technologies Appoints Industry Leader Kevin Trapp as Chief Commercial Officer

Nov 3, 2025, 4:30 PM EST - 6 months ago

DBV Technologies Appoints Industry Leader Kevin Trapp as Chief Commercial Officer

DBVT

DBV Technologies Announces Appointment of Philina Lee, Ph.D. to Board of Directors

Oct 30, 2025, 4:30 PM EDT - 6 months ago

DBV Technologies Announces Appointment of Philina Lee, Ph.D. to Board of Directors

DBVT

DBV Technologies to Participate in Upcoming ACAAI 2025 Annual Scientific Meeting

Oct 30, 2025, 3:00 AM EDT - 6 months ago

DBV Technologies to Participate in Upcoming ACAAI 2025 Annual Scientific Meeting

DBVT

DBV Technologies Announces Sale of approximately $30 million of ADSs Through its At-The-Market (ATM) Program on Nasdaq

Oct 29, 2025, 6:47 PM EDT - 6 months ago

DBV Technologies Announces Sale of approximately $30 million of ADSs Through its At-The-Market (ATM) Program on Nasdaq

DBVT

DBV Technologies Announces Resignation of Board Member

Sep 18, 2025, 4:30 PM EDT - 8 months ago

DBV Technologies Announces Resignation of Board Member

DBVT

DBV Technologies Establishes an At-The-Market (ATM) Program on Nasdaq

Sep 5, 2025, 4:30 PM EDT - 8 months ago

DBV Technologies Establishes an At-The-Market (ATM) Program on Nasdaq

DBVT

DBV Technologies announces filing of 2025 Half-Year Report ― Conditions for accessing or consulting the Report

Jul 29, 2025, 4:17 PM EDT - 10 months ago

DBV Technologies announces filing of 2025 Half-Year Report ― Conditions for accessing or consulting the Report

DBVT

DBV Technologies Reports Second Quarter and Half-Year 2025 Financial Results

Jul 29, 2025, 4:08 PM EDT - 10 months ago

DBV Technologies Reports Second Quarter and Half-Year 2025 Financial Results

DBVT

Half-Year Report on the DBV Technologies Liquidity Contract with ODDO BHF

Jul 28, 2025, 4:30 PM EDT - 10 months ago

Half-Year Report on the DBV Technologies Liquidity Contract with ODDO BHF

DBVT

DBV Technologies Announces Appointment of James Briggs as Chief Human Resources Officer

Jul 22, 2025, 4:30 PM EDT - 10 months ago

DBV Technologies Announces Appointment of James Briggs as Chief Human Resources Officer

DBVT

DBV Technologies Transcript: Study Update

Jun 25, 2025, 5:00 PM EDT - 11 months ago

DBV Technologies Transcript: Study Update

DBV Technologies Announces First Subject Screened in COMFORT Toddlers Supplemental Safety Study in Peanut Allergic Toddlers 1 – 3 Years Old

Jun 25, 2025, 4:15 PM EDT - 11 months ago

DBV Technologies Announces First Subject Screened in COMFORT Toddlers Supplemental Safety Study in Peanut Allergic Toddlers 1 – 3 Years Old

DBVT

DBV Technologies to Participate in Upcoming EAACI Congress 2025

Jun 12, 2025, 4:05 PM EDT - 11 months ago

DBV Technologies to Participate in Upcoming EAACI Congress 2025

DBVT

DBV Technologies Announces the Voting Results of its 2025 Combined General Meeting

Jun 11, 2025, 4:30 PM EDT - 11 months ago

DBV Technologies Announces the Voting Results of its 2025 Combined General Meeting

DBVT

DBV Technologies announces the filing of an addendum to the 2024 Universal Registration Document

Jun 3, 2025, 4:30 PM EDT - 1 year ago

DBV Technologies announces the filing of an addendum to the 2024 Universal Registration Document

DBVT

Combined General Meeting of June 11, 2025

May 15, 2025, 4:30 PM EDT - 1 year ago

Combined General Meeting of June 11, 2025

DBVT

DBV Technologies Transcript: The Citizens JMP Life Sciences Conference 2025

May 7, 2025, 11:00 AM EDT - 1 year ago

DBV Technologies Transcript: The Citizens JMP Life Sciences Conference 2025

DBV Technologies to Participate in the Citizens JMP Life Sciences Conference

May 5, 2025, 4:30 PM EDT - 1 year ago

DBV Technologies to Participate in the Citizens JMP Life Sciences Conference

DBVT

DBV Technologies Reports First Quarter 2025 Financial Results

Apr 30, 2025, 4:00 PM EDT - 1 year ago

DBV Technologies Reports First Quarter 2025 Financial Results

DBVT

DBV Technologies announces filing of 2024 Annual Report on Form 10-K and Universal Registration Document

Apr 11, 2025, 4:30 PM EDT - 1 year ago

DBV Technologies announces filing of 2024 Annual Report on Form 10-K and Universal Registration Document

DBVT

DBV Technologies Transcript: Status Update

Mar 31, 2025, 5:00 PM EDT - 1 year ago

DBV Technologies Transcript: Status Update

DBV Technologies ADRs Rise After Up to $306.9M in New Financing

Mar 28, 2025, 11:09 AM EDT - 1 year ago

DBV Technologies ADRs Rise After Up to $306.9M in New Financing

DBVT

DBV Technologies Announces Financing of up to $306.9 Million (€284.5 Million) to Advance Viaskin® Peanut Patch Through Biologics License Application Submission and U.S. Commercial Launch, if Approved

Mar 27, 2025, 10:30 PM EDT - 1 year ago

DBV Technologies Announces Financing of up to $306.9 Million (€284.5 Million) to Advance Viaskin® Peanut Patch Through Biologics License Application Submission and U.S. Commercial Launch, if Approved

DBVT

DBV Technologies Secures Agreement with FDA on Safety Exposure Data Required for BLA for Viaskin® Peanut Patch in 4–7-year-olds, Accelerating the Timeline for a BLA Filing Submission to 1H 2026, & Reports 2024 Unaudited Financial Results

Mar 24, 2025, 2:30 AM EDT - 1 year ago

DBV Technologies Secures Agreement with FDA on Safety Exposure Data Required for BLA for Viaskin® Peanut Patch in 4–7-year-olds, Accelerating the Timeline for a BLA Filing Submission to 1H 2026, & Reports 2024 Unaudited Financial Results

DBVT

DBV Technologies to Participate in Upcoming AAAAI/WAO Joint Congress

Feb 25, 2025, 4:01 PM EST - 1 year ago

DBV Technologies to Participate in Upcoming AAAAI/WAO Joint Congress

DBVT

DBV Technologies Transcript: Study Result

Jan 8, 2025, 5:00 PM EST - 1 year ago

DBV Technologies Transcript: Study Result

DBV Technologies Transcript: Status Update

Dec 11, 2024, 5:00 PM EST - 1 year ago

DBV Technologies Transcript: Status Update

DBV Confirms Alignment with U.S. FDA on Accelerated Approval Pathway for the Viaskin® Peanut Patch in Toddlers 1 – 3 Years-Old

Dec 11, 2024, 4:05 PM EST - 1 year ago

DBV Confirms Alignment with U.S. FDA on Accelerated Approval Pathway for the Viaskin® Peanut Patch in Toddlers 1 – 3 Years-Old

DBVT

DBV Technologies Announces Plan to Implement ADS Ratio Change

Nov 11, 2024, 4:30 PM EST - 1 year ago

DBV Technologies Announces Plan to Implement ADS Ratio Change

DBVT

DBV Technologies Reports Third Quarter 2024 Financial Results

Nov 6, 2024, 4:30 PM EST - 1 year ago

DBV Technologies Reports Third Quarter 2024 Financial Results

DBVT

DBV Technologies Transcript: Status Update

Oct 22, 2024, 5:00 PM EDT - 1 year ago

DBV Technologies Transcript: Status Update

DBV Announces Positive Regulatory Updates for the Viaskin® Peanut Patch in the United States and Europe

Oct 22, 2024, 4:45 PM EDT - 1 year ago

DBV Announces Positive Regulatory Updates for the Viaskin® Peanut Patch in the United States and Europe

DBVT

DBV Technologies to Participate in Upcoming ACAAI 2024 Congress

Oct 18, 2024, 4:30 PM EDT - 1 year ago

DBV Technologies to Participate in Upcoming ACAAI 2024 Congress

DBVT

DBV Technologies Completes Screening for the VITESSE Phase 3 Clinical Trial

Sep 23, 2024, 4:30 PM EDT - 1 year ago

DBV Technologies Completes Screening for the VITESSE Phase 3 Clinical Trial

DBVT

DBV Technologies Transcript: H.C. Wainwright 26th Annual Global Investment Conference 2024

Sep 9, 2024, 3:00 PM EDT - 1 year ago

DBV Technologies Transcript: H.C. Wainwright 26th Annual Global Investment Conference 2024

DBV Technologies to Participate in the H.C. Wainwright 26th Annual Global Investment Conference

Sep 4, 2024, 4:30 PM EDT - 1 year ago

DBV Technologies to Participate in the H.C. Wainwright 26th Annual Global Investment Conference

DBVT

DBV Technologies Announces Filing of 2024 Half-Year Report ― Conditions for Accessing or Consulting the Report

Jul 30, 2024, 5:30 PM EDT - 1 year ago

DBV Technologies Announces Filing of 2024 Half-Year Report ― Conditions for Accessing or Consulting the Report

DBVT

DBV Technologies Earnings Call Transcript: Q2 2024

Jul 30, 2024, 5:30 PM EDT - 1 year ago

DBV Technologies Earnings Call Transcript: Q2 2024

DBV Technologies Provides Updates on the Viaskin Peanut Program in Children and Toddlers and Reports Second Quarter and Half-Year 2024 Financial Results

Jul 30, 2024, 4:30 PM EDT - 1 year ago

DBV Technologies Provides Updates on the Viaskin Peanut Program in Children and Toddlers and Reports Second Quarter and Half-Year 2024 Financial Results

DBVT

DBV Technologies to Report Second Quarter 2024 Financial Results and Business Update on July 30, 2024

Jul 29, 2024, 1:30 AM EDT - 1 year ago

DBV Technologies to Report Second Quarter 2024 Financial Results and Business Update on July 30, 2024

DBVT

DBV Technologies Transcript: Goldman Sachs 45th Annual Global Healthcare Conference

Jun 10, 2024, 8:00 AM EDT - 2 years ago

DBV Technologies Transcript: Goldman Sachs 45th Annual Global Healthcare Conference

DBV Technologies to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference

Jun 5, 2024, 4:30 PM EDT - 2 years ago

DBV Technologies to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference

DBVT

DBV Technologies to Participate in Upcoming EAACI 2024 Congress

May 30, 2024, 4:30 PM EDT - 2 years ago

DBV Technologies to Participate in Upcoming EAACI 2024 Congress

DBVT

DBV Technologies Transcript: H.C. Wainwright 2nd Annual BioConnect Investor Conference at NASDAQ

May 20, 2024, 12:00 PM EDT - 2 years ago

DBV Technologies Transcript: H.C. Wainwright 2nd Annual BioConnect Investor Conference at NASDAQ

DBV Technologies Announces Results of its 2024 Combined General Meeting

May 16, 2024, 4:30 PM EDT - 2 years ago

DBV Technologies Announces Results of its 2024 Combined General Meeting

DBVT

Mortimer2020
Mortimer2020 Apr. 8 at 2:10 PM
$DBVT where are we at with getting this thing to market
0 · Reply
focafoca99
focafoca99 Apr. 3 at 9:02 PM
$DBVT release the monthly share-count and voting-rights disclosure as of March 31.
0 · Reply
WallStreetBuyDip
WallStreetBuyDip Apr. 3 at 6:13 PM
$DBVT Massive volume spike of 446,600 shares traded, well over 2x the average volume. Price staying around $21.06, with highs at $24.54 and lows at $6.50. Recent price action has been quite active with significant volume increases. Waiting for a lower H% before considering entry.
0 · Reply
RunnerSignals
RunnerSignals Apr. 3 at 1:27 PM
$VSAT $AAOI $AXTI $KURA $DBVT RSI flip = early money signal not extended yet, setups still developing https://stocksrunner.com/news/2026-04-03-momentum-rsi-breakout
0 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Mar. 26 at 12:23 PM
$DBVT RSI: 40.70, MACD: -0.4956 Vol: 1.38, MA20: 21.02, MA50: 21.42 🟢 BUY - Uptrend + healthy RSI 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
OpenOutcrier
OpenOutcrier Mar. 25 at 12:14 PM
$DBVT (+5.6% pre) DBV Technologies to Join CAC Mid 60 and SBF 120 Indices Following Euronext Paris Annual Review https://ooc.bz/l/97133
0 · Reply
thejaygatsby
thejaygatsby Mar. 24 at 2:14 PM
$DBVT earnings are today right?
0 · Reply
Zamboni18
Zamboni18 Mar. 12 at 1:40 PM
$DBVT
0 · Reply
medguy
medguy Mar. 12 at 4:16 AM
Looking for bounce $DBVT
0 · Reply
focafoca99
focafoca99 Mar. 3 at 10:47 PM
$DBVT dropped a voting-rights/share-count update.
0 · Reply
kriks2611
kriks2611 Mar. 2 at 9:56 PM
$DBVT
0 · Reply
notreload_ai
notreload_ai Mar. 2 at 4:10 PM
$DBVT reveals new VITESSE Phase 3 data at AAAAI 2026: 83% of kids on VIASKIN Peanut Patch increased safe peanut dose vs 48% on placebo, with excellent safety. https://notreload.xyz/kids-tolerate-more-peanut-with-viaskin-patch-in-landmark-study/
0 · Reply
OpenOutcrier
OpenOutcrier Mar. 2 at 1:37 PM
$DBVT (+1.4% pre) Phase 3 VITESSE data highlighted by DBV Technologies https://ooc.bz/l/95114
0 · Reply
AlertsAndNews
AlertsAndNews Feb. 28 at 8:46 PM
$DBVT DBV Technologies Highlights Additional Data from Successful Phase 3 VITESSE Study at the AAAAI 2026 Annual Meeting "Approximately 83% of children treated with the VIASKIN® Peanut Patch increased their eliciting dose at month 12, compared to approximately 48% in the placebo group Approximately 60% of children treated with the VIASKIN® Peanut Patch increased their eliciting dose by at least two doses at month 12, compared to 23% in the placebo group"
0 · Reply
Lalalilala
Lalalilala Feb. 25 at 8:20 PM
$DBVT This is bad news, coming just two days before a Phase 3 data presentation. Run before it drops to $8 on Monday. 😩
0 · Reply
Lalalilala
Lalalilala Feb. 24 at 8:59 PM
$DBVT up . Spéculation thursday expect 26$.
0 · Reply
BillionerOfKing
BillionerOfKing Feb. 23 at 8:48 PM
$DBVT Current Stock Price: $21.14
1 · Reply
RodneyHammons200
RodneyHammons200 Feb. 21 at 7:15 AM
$DBVT DBV Technologies develops allergy immunotherapy treatments. Clinical trial outcomes drive valuation. Funding risk remains significant.
0 · Reply
FadeChaser
FadeChaser Feb. 18 at 9:17 AM
$DBVT Rare disease biotech where regulatory pathways define upside.
1 · Reply